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ABSTRACT
Introduction Reported outcomes for older people with 
advanced chronic kidney disease (CKD) often focus 
on survival and mortality and little attention is paid 
to symptom burden and health- related quality of life. 
Recognising frailty and providing interventions that may 
improve outcomes have been studied in the general 
population with a growing research interest within CKD.
Methods and analysis A scoping review will be 
undertaken following a recommended process to 
understand relevant research and priorities for older 
people living with frailty and advanced CKD. Databases will 
be searched and following a systematic process by a core 
team, a final list of included studies will be analysed. Focus 
groups will then be conducted with older people with 
advanced CKD to incorporate stakeholder views.
Ethics and dissemination Our scoping review will 
use robust methodology to identify relevant literature 
focused on outcomes and care priorities for older people 
with advanced CKD. Ethical approval will be sought to 
conduct the focus groups. The result of this review will 
be disseminated through patient networks and national 
conferences. The interdisciplinary team collaborating plan 
to continue work in this area to improve the care and 
management of older people with advanced CKD.
BACKGROUND
The ageing population is a major concern for 
both health and social care across the UK.1 
The construct of frailty, which recognises the 
multidimensional patterns of decline in older 
people, has been used to categorise vulner-
able older adults at greatest risk of adverse 
health outcomes.2 This increased risk has 
driven the need to identify frailty and associ-
ated geriatric syndromes among older people 
and offer a personalised management plan 
that aims to improve outcomes.2–4 Frailty 
arises from a combination of reduced resil-
ience and increased vulnerability associated 
with ageing. The British Geriatric Society 
defines frailty as ‘a distinctive health state 
related to the ageing process in which multiple body 
systems gradually lose their in- built reserves dimin-
ishing the ability to carry out important practical 
and social activities’.5 There are two principal 
conceptual models of frailty, specifically the 
deficit accumulation model of frailty (opera-
tionalised as the Frailty Index) and the phys-
ical model of frailty (often referred to as the 
Frailty Phenotype).3 6 7 Although differing 
in their underlying theories, both predict 
increased vulnerability to adverse outcomes. 
Since their publication, several screening 
tools have been derived that aim to offer a 
more clinically practical approach to frailty 
identification.8
Frailty is not just a concern for geriatric 
medicine; studies within specialty medicine, 
including nephrology, have demonstrated 
the association between frailty and health 
outcomes in their respective patient popu-
lations.9 Reports of outcomes relevant to 
Strengths and limitations of this study
 ► This is the first review to focus on outcome priori-
ties for older people living with frailty and advanced 
chronic kidney disease (CKD).
 ► The research group has a breadth of expertise, in-
cluding patient representatives and interdisciplinary 
members.
 ► A rigorous process will be followed to identify and 
select studies, but these will not be subject to an 
in- depth assessment of quality.
 ► The review will include a comprehensive range of 
peer- reviewed and grey literature but limited to 
English language papers.
 ► Older people living with frailty and advanced CKD 
and carers will share their perspectives on the find-
ings and integrated into the final report.
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older people living with frailty in the general popula-
tion cannot be generalised to those with chronic kidney 
disease (CKD) as there are notable differences between 
those who are frail with CKD and those who are frail with 
normal kidney function.2 10 Differences include increased 
falls, hospitalisation, lower health- related quality of life 
(HRQoL), increased symptom burden and mortality 
rate.10–21 Furthermore, studies that have investigated 
frailty in CKD populations not only report a higher 
prevalence of frailty but also frequently report frailty in 
younger age groups, potentially reflecting alternative 
drivers of the frailty syndrome in CKD. Importantly, it is 
not clear which outcomes are most important for older 
people living with frailty and advanced CKD.
Studies that focus on older people with advanced 
CKD typically focus on morbidity and mortality.22 These 
outcomes are unarguably relevant, although symptom- 
burden, HRQoL and other patient- reported outcomes 
are also important. For example, when choosing between 
treatment options, patient decision- making is informed 
by not only survival outcomes but also lifestyle, HRQoL 
and preferences for end- of- life care.23 24 Outcomes that 
are important for frail adults in the general popula-
tion have been reported25 but unlikely to be the same 
as for frail adults with advanced CKD, and may not be 
relevant given the complexities of renal replacement 
therapy (RRT). Equally, outcomes important for patients 
with CKD in general are unlikely to be the same as for 
frail adults with the same condition. Although the Stan-
dardised Outcomes in Nephrology (SONG) initiative is 
working towards establishing core outcomes in CKD22 
and the James Lind Alliance26 has recommended research 
priorities for patients living with frailty, to our knowledge, 
no group has yet looked at both groups in conjunction.
The comprehensive geriatric assessment (CGA) is a 
model of healthcare based on comprehensive multi-
disciplinary assessment taking account of medical, 
psychological, functional, social and environmental 
problems. The CGA is the recognised gold standard 
of care for older people living with frailty admitted to 
secondary care2 27 and has also been recommended 
in primary care settings.27 A recent systematic review 
identified a need for further research evaluating the 
role of a geriatric assessment in the advanced CKD 
population.28 This is also supported by the European 
Renal Best Practice Working Group emphasising the 
need ‘to identify those who would benefit from more 
in- depth geriatric assessment and rehabilitation’ 
and recommending further research in this area.29 
A recent umbrella systematic review of the CGA indi-
cated that key outcomes reported within existing 
reviews of the CGA in older adults without CKD were 
death, disability and institutionalisation, reduced 
length of stay and readmission, while patient- reported 
outcomes (PROMs) and HRQoL measures were 
fewer and reported less frequently.30 The focus of the 
CGA is to encompass a holistic approach to improve 
outcomes for people living with frailty relating to social 
and functional abilities and these potential gaps on 
important outcomes for older people living with frailty 
and advanced CKD.
This scoping review will identify and summarise existing 
evidence relating to relevant research and priorities for 
older people living with frailty and advanced CKD. The 
proposed investigation is part of a UK- wide collaborative 
working group of interprofessional experts, including 
clinicians, nurses, allied health professionals, health 
psychologists, decision scientists and applied health 
researchers. Research has highlighted that the experi-
ence of older people living with frailty and CKD is often 
not ‘heard’ by their healthcare professionals, emphasising 
the need to also understand the perspectives of people 
living with frailty and CKD, and their carers.31 The collab-
orative working group aims to identify research priorities 
and inform the design of improved models of care for 
older patients with advanced CKD.
This project will be conducted in accordance with the 
study protocol and the ethical principles outlined by 
Good Clinical Practice (GCP) and the Declaration of 
Helsinki.
Aim
The aim of this scoping review is to identify and 
summarise existing evidence relating to relevant 
research and priorities for older people living with frailty 
and advanced CKD (stages 4–5). Following preliminary 
discussion within the multiprofessional review team and 
a stakeholder group, comprising older people living with 
advanced CKD and their carers and family members, 
we identified four broad topics for further exploration 
within this review:
 ► Frailty identification and assessment methodology.
 ► Quantitative and qualitative outcomes reported for 
older people living with frailty and advanced CKD.
 ► Studied interventions that aim to improve outcomes 
for older people living with frailty and advanced 
CKD, including but not limited to survival, HRQoL, 
functional- ability, self- care, decision- making and 
cognition.
 ► How care priorities for older people living with frailty 
and advanced CKD can be better understood.
METHODS
The scoping review strategy follows a five- staged frame-
work described by Arksey and O’Malley in 2005, which 
is outlined below under the headings that describe the 
process. The PRISMA- ScR guidelines for scoping reviews 
will also be used to guide the methods and ensure a 
systematic approach is followed. On completion of this 
review, they will be included as a checklist and appendix.32 
The broad nature of scoping reviews requires a focus on 
summarising the breadth of evidence leading to a clearly 
articulated scope of inquiry.33 The questions identified 
below emphasise the importance of clarity in the concept, 
the population and outcomes of interest in order to 
develop an effective search strategy.33
 on M









pen: first published as 10.1136/bm





3Hurst H, et al. BMJ Open 2021;11:e040715. doi:10.1136/bmjopen-2020-040715
Open access
Members of the research team form the collaborative 
group, although a core group will act as the review team 
including an expert in scoping review methodology.
Stage 1: identifying the research question
The broad research questions used in the initial scoping 
process include:
 ► What outcomes have been reported in older people 
living with frailty and advanced CKD?
 ► What interventions have been reported and how 
might they enhance both care and outcomes specifi-
cally for older people with advanced CKD?
 ► Is frailty formally identified in this population and if 
so what methods are used to identify frailty?
 ► What outcomes matter most to older people (living 
with frailty and advanced CKD), their relatives and 
carers?
In keeping with the recommended iterative method-
ology of scoping reviews, the research questions may be 
refined further as the review progresses.
Inclusion and exclusion criteria
The initial inclusion and exclusion criteria have been 
written to focus the search strategy but may need to be 
altered at later stages of the review process.
Inclusion criteria
 ► Population: Older people (aged ≥65 years) with 
advanced CKD (stages 4 and 5), who may be receiving 
RRT, conservative care or have received a renal trans-
plant, and carers/families of these individuals. People 
aged ≥65 years were defined as ‘older’, in accordance 
with the definitions used by NHS England.34 Other 
studies that include a wide age range will only be 
included if outcomes for a ≥65- year- old subgroup are 
reported.
 ► Studies: All study designs (including systematic 
reviews, qualitative research and grey literature) that 
include older people with advanced CKD, carers/
families in line with the population inclusion criteria 
outlined including frailty as a descriptor.
 ► Interventions: Where interventions are the focus of a 
study, all types of interventions, delivered at any level 
from individual to service level will be included.
 ► Outcomes: Health- related outcomes, HRQoL, 
symptom burden, patent experience, functional and 
cognitive ability, life participation (this list is not 
exhaustive and more may be included).
Exclusion criteria
 ► Studies not including >65- year- old population and 
studies where subgroup analysis is not possible in this 
age group.
 ► Studies not published in English.
 ► Studies prior to 1995.
Initially, the search strategy will exclude studies that 
do not specifically measure frailty or use frailty as a term 
within the study. This is to provide focus as described 
above and in the initial searching it became clear this was 
required to refine the search strategy. Studies are limited 
to after 1995 to ensure that they are relevant to clinical 
practice but also as the nosological term frailty is not well 
reported before 2000.35 Studies not published in English 
will be excluded due to cost and time constraints. This 
may limit review findings and will be acknowledged in the 
final summary.
Stage 2: identifying relevant studies
Literature searches
A comprehensive and iterative approach to identify 
evidence from a range of study designs will be taken. The 
search will be guided by a health information specialist 
and incorporate resources that reflect different disci-
plines while taking a pragmatic approach to meet the 
required deadlines and resources.
Resources searched
These are provided in table 1. Searches will be conducted 
in three phases: first, scoping (to gauge the volume 
available and develop/refine the protocol, inclusion 
and exclusion criteria); second, more comprehensive 
searches (main literature searches in line with the major 
resources set out in table 2); and the final stage will be 
confirming, this involves identification of other sources of 
information including grey literature and will be decided 
with further discussion within the core team (searches of 
reference lists of identified reports/literature, focused 
website searches, consultation with experts and addi-
tional searches following discussions in the sifting phase). 
The inclusion of grey literature is recommended and will 








Web of Science/Web of Knowledge Science/Social 
sciences
Scopus General, grey 
literature
Social Care Online Social care, grey 
literature
ASSIA Social science




Renal Association, British Renal 
Society and NICE, EDTNA/ERC, 
International Nephrology Societies 















pen: first published as 10.1136/bm





4 Hurst H, et al. BMJ Open 2021;11:e040715. doi:10.1136/bmjopen-2020-040715
Open access 
Search terms (thesaurus and free text)
This will be identified by scoping searches, an exhaus-
tive list generated by the project team, consulting with 
the collaborative group and through scoping searches 
of a small sample of databases. The search will be wide 
and sensitive to encompass the full range and diversity 
of perspectives of frail older people with advanced CKD. 
Search terms used are presented in table 2.
Process of searching
The searches will be undertaken by a research asso-
ciate with supervision from an experienced information 
specialist. Outcomes of the searches will be stored on 
Endnote web reference management software to enable 
sharing across the core team and to allow the team to 
track references throughout the review process. Each 
search strategy will be recorded to provide a complete 
history of the search process and to provide transparency 
of the process.
Stage 3: study selection
Once the material located in the search stage has been 
uploaded to Endnote Reference Management Data-
base, core review team members will use the inclusion 
and exclusion criteria to sift the material. The initial 
sift will use the study title to identify potentially relevant 
studies, five members of the team will be involved in this 
process to ensure consistency. The next sift will be based 
on title and abstract by two members of the team inde-
pendently. The third stage will be full article text review, 
again conducted by two members independently. Docu-
ments will be grouped into relevant areas identified by 
the collaborative group; for example, it may be better to 
group according to their treatment option, for example, 
haemodialysis. There is likely to be wide variation and a 
great deal of heterogeneity in studies involving this partic-
ular population. This final third stage (full text sift) will 
aim to assess the extent, scope and quality of potential 
evidence; this will be a full- text review to create the final 
list of included studies. If only abstracts were obtained, 
they will be included for review. This will be done in 
duplication, independently by two reviewers to reduce 
errors and increase validity. We will develop a rapid 
review assessment tool, based on the inclusion criteria. 
The core team (five members: HH, PO, AB, EJ, ACN and 
HY) will be involved at all stages to strengthen the exper-
tise of the context and methodological considerations. 
Decisions made will be documented and recorded using 
Endnote library so a clear decision- making trail is visible. 
If there is any disagreement regarding potential included 
studies, the wider collaborative team will be consulted. 
online supplemental figure 1 represents the stages of the 
scoping review.
Stage 4: charting the data
This stage of the review involves extracting key elements 
of the papers to provide an overview and map of the 
evidence. These elements have been agreed with the 
collaborative group and will be recorded in tabular form 
in Excel spreadsheets under the following suggested 
headings:
1. Author details and date.
2. Country
3. Aims of the study.
4. Participants and age ranges.
5. Stage of kidney disease and/or dialysis modality.
6. Outcomes mapped to the International Classification 
for Functioning for Disability and Health Framework 
(ICF).36
7. Geriatric domains studied and frailty assessments used.
8. Study design.
9. Key findings.
Table 2 Search terms
1 2 3
Chronic kidney disease or 
CKD (ti,ab)
Aged (ti,ab) Frail (ti,ab)
Renal insufficiency (ti,ab) Aged (exp) Frailty (exp)
Chronic kidney failure (ti,ab) Geriatric (ti,ab) Frail 
elderly/frail 
(exp)
Chronic renal failure (ti,ab) Geriatric (exp)   
Chronic kidney disease (ti,ab) Elderly (ti,ab)   
Chronic kidney disease (ti,ab) Old (ti,ab)   
Chronic renal disease (ti,ab) Old (exp)   
Renal failure (ti,ab)     
End- stage renal disease (ti,ab)     
End- stage kidney disease 
(ti,ab)
    
End- stage renal failure (ti,ab)     
End- stage kidney failure (ti,ab)     
Established kidney disease 
(ti,ab)
    
Advanced chronic renal 
disease or CKD (ti,ab)
    
End -stage renal disease (ti,ab)     
End -stage renal failure (ti,ab)     
Renal insufficiency (ti,ab)     
Dialysis (ti,ab)     
Renal replacement therapy 
(ti,ab)
    
Kidney replacement therapy 
(ti,ab)
    
Renal replacement therapy 
(exp)
    
Renal transplant (ti,ab)     
Kidney transplant (ti,ab)     
Search looks at any terms in column 1: PLUS any terms in column 
2: PLUS any terms in column 3.
CKD, chronic kidney disease; exp, term exploded to incorporate 
narrower terms; ti,ab, looked in title and abstract.
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The ICF will provide a recognised framework for 
reporting the outcomes used, and the interventions 
described within studies included in this review. The 
ICF provides a classification of health and health- related 
domains, including body function and structure, activity 
and participation. The ICF is the WHO’s means of meas-
uring functioning in society irrespective of impairment, 
and its use will allow gaps in intervention provision 
and outcome measurement to be readily identified.36 
The broad categories of impairments of body function 
and structure, activity and participation will be used to 
examine outcomes and interventions reported in the 
studies included within this scoping review and provide a 
standard structure for reporting findings.37 Examples of 
impairments in body function and structure may include 
outcomes such as measures of muscle strength, fatigue, 
mood, balance, cognition, activity (eg, mobility/walking 
and activities of daily living, such as personal care and 
meal preparation) and participation (eg, ability to engage 
in relationships, social roles and community life).
Quality assessments are not typically required in 
scoping reviews, as scoping studies are not designed to 
provide a weighting of robust quality evidence or general-
isability of results.38 A rigorous process will be followed to 
identify and select studies, but these will not be subject to 
an in- depth assessment of quality.
Stage 5: collating, summarising and reporting the results
The scoping review process is iterative by design. It is 
essential to provide a clear process outlining how the 
included studies answer the key aims and questions. 
Initially, the primary analysis will use the tables created in 
stage 4 to collate and categorise all studies by the agreed 
criteria. The first tables may be categorised according to 
prevalence and measures of frailty, or according to RRT 
modality, and the evidence relating to each presented. 
The ICF framework will be used to map outcomes relevant 
to health and disability as described earlier. These tables 
will then guide the synthesis and be used in the narrative 
descriptive approach applicable to scoping reviews.33 38
Scoping reviews often include stakeholder engagement 
involving people with lived experience, their carers and 
family members.38 Therefore, the final stage of the review 
will use focus group discussions to capture patient and 
carer/family perspectives on the findings of the scoping 
review. The focus groups will take place within an NHS 
hospital single centre setting. During the focus group, 
participants will be presented with the key findings of 
the review. Nominal group technique (NGT), which is a 
structured, systematic, transparent and inclusive method 
for rapidly reaching consensus, will be used to develop 
consensus. The aim would be to develop research prior-
ities in this population, carer preferences, group and 
preferred outcome measures.39 40 The NGT process will 
involve asking participants to generate ideas related to 
the key findings, share and discuss them, and finally vote 
and rank them in order of priority.
A purposeful approach will be used to identify individ-
uals >65 years identified as frail using the Clinical Frailty 
Scale. Potential participants including family members 
and carers attending clinics in one centre will be 
approached. We will also monitor other important char-
acteristics such as gender, ethnicity and stage of CKD/
form of RRT to ensure diverse views are captured. The 
results of the consensus process will be integrated into 
the key findings from the scoping review with reference 
to the review questions and aims.
Data and protection
The data collected on the participants will be anony-
mised. The recorded data will be transcribed but remain 
anonymous with only the participant ID number for the 
study on all documentation. Other members of the team 
will have access to the data as part of the analysis but it will 
remain anonymised.
Patient and public involvement
Patient representatives have been involved in the design 
of the scoping review from the outset and embedded as 
equal partners within the research group. Two key patient 
leaders have contributed to the writing of the grant 
proposal and this protocol. Feedback from several kidney 
patient involvement groups indicated that there was 
strong support for developing a programme of research 
to address the specific needs of older people living with 
frailty and advanced CKD.
Monitoring and governance
The study will be subject to the audit and monitoring 
regimen of the Manchester University NHS Foundation 
Trust (MFT) and follows the MFT Governance protocol.
Ethics and dissemination
We anticipate publishing these results and continuing 
the collaboration of the wider interdisciplinary team 
involved in this review to formulate key, relevant and 
focused research. This review is funded by the British 
Renal Society and Kidney Research UK grants committee 
and findings will be published through their networks 
and disseminated at national meetings. Two members of 
the collaborative group are people living with CKD, who 
will ensure these findings are also published within their 
national networks. Ethical approval has been granted for 
the focus group component of this study, and its findings 
will further elucidate the care and research priorities for 
this group.
DISCUSSION
In summary, this review brings together a multiprofes-
sional team of experts to identify and summarise existing 
evidence relating to relevant research and priorities 
for older people living with frailty and advanced CKD. 
Patient involvement in care, shared decisions about their 
care and increasing advanced care planning have all been 
cited as important.41–43 There is concern that we have a 
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growing older population with advanced CKD with an 
increased prevalence of frailty. Bringing older people 
with CKD and their carers together and asking them what 
they think is important to ensure the patient and carer 
voices are represented.
Indemnity
This study will be covered by the NHS indemnity scheme.
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